Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. - Long, G.V.; Arance, A.; Mortier, L.; Lorigan, P.; Blank, C.; Mohr, P.; Schachter, J.; Grob, J.-J.; Lotem, M.; Middleton, M.R.; Neyns, B.; Steven, N.; et al. (Annals of Oncology, 2022)